Biomonitor was founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen and has since its inception grown rapidly.

The foundation of the company is based on Professor Klaus Bendtzen’s many years of experience from his research work at the Copenhagen University Hospital on inflammation and immunology. Prof. Klaus Bendtzen discovered through his work how some patients form antibodies against those proteins and peptides that are used in biopharmaceutical products for the treatment of a range of chronic diseases. Antibodies can neutralize the biopharmaceuticals that patients receive and patients with antibodies thereby do not or only marginally benefit from such treatments so it became crucial to develop methods to monitor biopharmaceuticals.

Biopharmaceutical treatments are very costly and potentially dangerous. Consequently, it makes good sense to monitor patients so that the drugs can be tailored to the individual patient and so that physicians early on can deal with patients who develop antibodies. By doing this, patients, society and insurance companies can save tremendous amount of resources and the patient can be relieved from a treatment that does not work as designed. Most biopharmaceutical treatments are relatively new, and Biomonitor is one of the leading companies in the field, which monitors these therapies.

In November 2008 Biomonitor acquired Neutekbio Ltd. With its proprietary platform of products based on reporter gene technology and developed cell-based assays and kits called iLite^™, Neutekbio Ltd. complements Biomonitor’s offerings in assays for patient monitoring and biopharmaceutical drug development programs. The discovery research is performed through a collaborative research and development agreement with the Laboratory of Viral Oncology (The Centre National Recherché Scientifique) in the Institute Andre Lwoff, Villejuif, France. These research programs have been carried out under the direction of Dr. Michael Tovey, an international leader in cytokine research and interferon therapy.

Back to About us